Ireland

--:--IST

Latest

Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact

Registers› Irish medicines ›Recombinant human igg1 monoclonal antibody to fibroblast growth factor 23

Medicines register · Ireland

Recombinant human igg1 monoclonal antibody to fibroblast growth factor 23 — medicines in Ireland

3 authorised products containing Recombinant human igg1 monoclonal antibody to fibroblast growth factor 23, from the HPRA register.

Download CSV

Source: HPRA open dataset ("Authorised or Transfer Pending Products"), CC BY 4.0. Complete coverage — all 10,295 authorised products are in this register. Synced 06 Oct 2026, 03:23 UTC

Narrow the register Reset

Search within results

Matches brand name, active substance, licence holder and licence number.

Browse by first letter

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0–9

Medicine

Active substance

Licence holder

Status

CRYSVITA 10 mg solution for injection EU/1/17/1262/001

Recombinant human igg1 monoclonal antibody to fibroblast growth factor 23

Kyowa Kirin Holdings B.V.

—

CRYSVITA 20 mg solution for injection EU/1/17/1262/002

Recombinant human igg1 monoclonal antibody to fibroblast growth factor 23

Kyowa Kirin Holdings B.V.

—

CRYSVITA 30 mg solution for injection EU/1/17/1262/003

Recombinant human igg1 monoclonal antibody to fibroblast growth factor 23

Kyowa Kirin Holdings B.V.

—

Cite this view

Priya Life Science (2026). Irish Medicines Register, filtered. Derived from the HPRA open dataset. Retrieved 6 October 2026. https://priyalifescience.com/medicines/substance/recombinant-human-igg1-monoclonal-antibody-to-fibroblast-growth-factor-23

Download this register

GET /api/export.php?register=medicines-ie&format=csv Try the JSON export →

Regulatory information only — not medical advice. For the authoritative record see the HPRA register directly.